

Director/PDMR Shareholding
RNS Number : 8629V
Roquefort Therapeutics PLC
04 February 2025

4 February 2025

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, advises that Stephen West, Executive Chairman and Ajan Reginald, CEO have purchased ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:

| Director | Number of Ordinary Shares Acquired | Average Price Paid per Share | Total Consideration Paid | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
|-----------------|---|-------------------------------------|---------------------------------|---|--------------------------------------|
| Stephen West* | 400,000 | 2.57 pence | £10,338.85 | 6,710,853 | 4.9% |
| Ajan Reginald | 191,059 | 2.60 pence | £5,000.00 | 12,537,472 | 9.2% |

*4,628,485 of Mr West's Ordinary Shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.

-ENDS-

Enquiries:

| | |
|--|-------------------------|
| Roquefort Therapeutics plc | +44 (0)20 3918 8633 |
| Stephen West (Chairman) / Ajan Reginald (CEO) | |
| SP Angel Corporate Finance LLP (Broker) | +44 (0) 20 3470 0470 |
| David Hignell / Vadim Alexandre / Devik Mehta | |
| Burson Buchanan (Public Relations) | +44 (0)20 7466 5000 |
| Ben Romney / Jamie Hooper / George Beale | |
| Peak IR (Investor Relations) | +33 (0)7 44 44 15 42 |
| Seb Wykeham | |

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immunology and oncology markets prior to partnering with big pharma.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK cell-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

| | | | |
|----------|--|---|-----------|
| 1 | Details of the person discharging managerial responsibilities / person closely associated | | |
| a) | Name | Stephen West | |
| 2 | Reason for the notification | | |
| a) | Position/status | Executive Chairman | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 par value | |
| | Identification code | ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Purchase of 400,000 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | 2.57 pence per share | 400,000 |
| d) | Aggregated information | | |
| | - Aggregated volume | - | 400,000 |
| | - Price | - | 2.57p |
| e) | Date of the transactions | | |
| | | 4 February 2025 | |
| f) | Place of the transactions | | |
| | | London Stock Exchange (XLON); Main Market | |

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

| | | | |
|----------|--|--|-----------|
| 1 | Details of the person discharging managerial responsibilities / person closely associated | | |
| a) | Name | Ajan Reginald | |
| 2 | Reason for the notification | | |
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 par value | |
| | Identification code | ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Trust distribution of 34,432 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | 2.6 pence per share | 191,059 |
| d) | Aggregated information | | |
| | - Aggregated volume | - | 191,059 |
| | - Price | - | 2.6p |
| e) | Date of the transactions | | |
| | | 4 February 2025 | |
| f) | Place of the transactions | | |
| | | London Stock Exchange (XLON); Main Market | |

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and

conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBGGDDSUGDGUS